Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
  • ECCO 2022
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018

Drug Discovery & Development

December 1, 2014

ABIVAX Completes First-In-Man Study of HIV Treatment

BioSpace

December 1, 2014

ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV.

  • 1
  • …
  • 43
  • 44
  • 45
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+